Which bladder sparing surgery is better when performing trimodal treatment of high-grade muscle invasive bladder cancer?


  • P.G. Yakovlev O. Bogomolets National Medical University, Ukraine
  • D.A. Klyushin T. Shevchenko Kyiv National University, Ukraine
  • A.V. Sakalo SE "Instite of Urology of NAMS of Ukraine", Ukraine




high-grade bladder cancer, bladder sparing surgery, partial cystectomy, TURB, recurrence, recurrence-free survival


Trimodal treatment (TMT) is considered an alternative to radical cystectomy in selected patients with muscle-invasive bladder cancer. This includes resection of the bladder, radiotherapy to the pelvis, and concomitant chemotherapy. Key to success of organ-sparing approach and high cancer-specific survival is performance of maximal resection of the cancer in the bladder. Transurethral resection of the bladder cancer (TURB) as main element of TMT is known as a surgery with high risk of local recurrence. Purpose of this work: is to compare the frequency of local recurrence and recurrence-free survival (RFS) of patients with high-grade bladder cancer (HGBC) after bladder-sparing surgeries: TURB and partial cystectomy (PCE). Materials and methods. We retrospectively analyzed medical records of 409 patients with HGBC who underwent radical bladder sparing surgery (either TURB or PCE) in 1998-2016. RFS was analyzed with Kaplan-Meier method. Test of equality of two survival functions for TURB and PCE was performed with three statistical tools (log-rank, Wilcoxon, Tarone-Ware) at significance level of 0.05. Results. TURB was done on 281 patients, PCE - 128 patients. Recurrences were diagnosed after 64 (15,6%) surgeries. After PCE the HGBC recurred more often than after TURB, 28 cases (after 21.9% PCE), vs. 36 cases (after 12.8% TURB) respectively. Median time to recurrence after PCE was 888 days, and 543 days after TURB. There was no statistically significant difference in RFS after two types of bladder sparing surgeries (р=0.195). Results of RFS after 1, 2 and 5 years after TURB and PCE were 47%, 22% та 6%, versus 54%, 36% та 18%, respectively. Conclusions. Local recurrences of HGBC after organ-preserving surgeries were diagnosed in 15.6% patients, and were more frequent after partial cystectomy (21.9% of cases), than after transurethral resection (12.8%). Median time to recurrence was 888 days after PCE, and 543 days after TURB, but RFS was not statistically different between these two surgeries (р=0.195).


Muscle-invasive and Metastatic Bladder Cancer. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona. EAU Guidelines Office, Arnhem, The Netherlands. , 2019.

Ploussard G., Daneshmand S., Efstathiou J.A. et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014. Vol. 66, No 1. P. 120­137.

Fahmy O., Khairul-Asri M. G., Schubert T. et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018. Vol. 36, No 2. P. 43­53.

Russell C. M., Lebastchi A. H., Borza T. et al. The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer. Bladder Cancer. 2016. Vol. 2, No 4. P. 381­394.

Giacalone N.J., Shipley W.U., Clayman R.H. et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017. Vol. 71, No 6. P. 952­960.

Gakis G., Efstathiou J., Lerner S.P. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013. Vol. 63, No 1. P. 45­57.

Chen R.C., Shipley W.U., Efstathiou J.A., Zietman A.L. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2013. Vol. 11, No 8. P. 952­960.

Flaig T.W., Spiess P.E., Agarwal N. et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018. Vol. 16, No 9. P. 1041­1053.

Tilki D., Shariat S.F., Lotan Y. et al. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013. Vol. 111, No 8. P. 1215­1221.

Clark P.E., Spiess P.E., Agarwal N. et al. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016. Vol. 14, No 10. P. 1213­1224.

Palou J., Pisano F., Sylvester R. et al. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World J Urol. 2018. Vol. 36, No 10. P. 1621­1627.

Cumberbatch M.G.K., Foerster B., Catto J.W.F. et al. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol. 2018. Vol. 73, No 6. P. 925­933.

Efstathiou J. A., Spiegel D.Y., Shipley W.U. et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012. Vol. 61, No 4. P. 705­711.

Krause F.S., Walter B., Ott O.J. et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res. 2011. Vol. 31, No 3. P. 985­990.